Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16024340 | 0.90 | SIGMAR1 (0.38) | SIGMAR1MEN1KMT2APOLBBCHE | |
| SCHEMBL16024321 | 0.90 | SIGMAR1 (0.38) | SIGMAR1BCHEKDM4EDRD2DRD4 | |
| SCHEMBL16024322 | 0.85 | SIGMAR1 (0.46) | SIGMAR1BCHEKDM4EDRD2DRD4 | |
| SCHEMBL15195727 | 0.83 | MPO (0.37) | SIGMAR1KMT2ABCHEDRD2DRD4 | |
| SCHEMBL16010829 | 0.82 | S1PR3 (0.53) | SIGMAR1 | |
| SCHEMBL16024318 | 0.82 | SIGMAR1 (0.46) | SIGMAR1SCN8AMEN1KMT2APOLB | |
| SCHEMBL16024316 | 0.80 | SIGMAR1 (0.60) | SIGMAR1BCHE | |
| SCHEMBL15806996 | 0.78 | SIGMAR1 (0.41) | SIGMAR1SCN8AMEN1KMT2APOLB | |
| SCHEMBL15195723 | 0.78 | HTR5A (0.37) | SIGMAR1KMT2ABCHEKDM4EDRD2 | |
| SCHEMBL15195718 | 0.77 | MMP2 (0.37) | SIGMAR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014138075-A1 | PHOSPHONIC ACID COMPOUNDS AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| US-20140256945-A1 | PHOSPHONIC ACID COMPOUNDS AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256945-A1 | PHOSPHONIC ACID COMPOUNDS AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS | S1PR1, S1PR2, S1PR5 | SIGMAR1 341/4885SCN8A 1794/4885MEN1 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.